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Abstract
Background
The number of bacterial strains resistant to antibiotics is growing exponentially.
Antibiotics are often prescribed more than needed, due to the delay period in diagnosing the
pathogen and giving treatment. This delay often pushes prescribers to give a broad-spectrum
antibiotic or pushes them to make the patient wait for the proper treatment, in turn allowing the
bacterium to potentially mutate. This creates a need for a more rapid, easily used, and cost
effective method of identifying pathogens. This study aimed to validate the CAPTURE™
method and its ability to identify pathogens, reduce the mechanical processing time, and
optimize the sample preparation and lysis protocols.

Methods
The methods for this project included several steps: captor design, sample acquisition,
sample prep, sample testing using the CAPTURE™ method, assay analysis, sample comparison,
and optimization. Urine samples were gathered from patients with suspected urinary tract
infections at the University of Alabama in Huntsville’s Faculty & Staff Clinic. Each patient
consented to give two urine samples, one sample was sent to the facility’s contracted lab for
routine identification. The second sample was sent to GeneCapture and considered discarded and
de-identified.

Results
To determine the accuracy of the CAPTURE™ assay pathogen identification, the results
from the contracted lab were compared to the results of the CAPTURE™ assay. The results
showed that the CAPTURE™ method has the ability to identify pathogens from the lysates.
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Introduction
The purpose of this research study is to test the validity and reliability of the
CAPTURE™ method, created by GeneCapture, Inc., a start-up company in the Biotechnology
field. The Confirming Active Pathogens Through Unamplified RNA Expression (the phrase
Confirming Active Pathogens Through Unamplified RNA Expression will be further noted as
CAPTURE™ in this text) method uses a molecular diagnostic technique to determine a genetic
match for the pathogen using DNA captors that will identify the pathogen in less than one hour
for minimal cost. CAPTURE™’s purpose is to rapidly diagnose bacterial and viral pathogens.
The need for a more rapid diagnostic testing method continues to grow exponentially as
antibiotic resistance increases, strains mutate, and cost of healthcare rises.
To begin the study, a partnership was cultivated between GeneCapture, Inc. and the
University of Alabama in Huntsville’s Faculty & Staff Clinic, a division of the College of
Nursing. Institutional Review Board approval was received from The University of Alabama in
Huntsville. (Appendix A) Patients that presented with symptoms of a urinary tract infection (the
phrase urinary tract infection will be further noted as UTI in this text) were recruited to
participate in the study and consented to give two urine samples (Appendix B, 1) (Appendix B,
2), one to be run through the CAPTURE™ method and the other sent for a culture and sensitivity
to the contracted laboratory for usual diagnostic tests and treatment.
The anticipated outcome of this research is the verification of CAPTURE™, through
comparative results, to correctly identify these common urinary tract pathogens. These findings
may advance further into other infectious pathogens and may be useful in correctly and rapidly
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facilities.
Background
Polymerase Chain Reaction
Polymerase chain reaction (denoted as PCR through the rest of the text) is a technique
used in many laboratories and development companies world wide. This technique was invented
in the 1980s and has been making many advances in recent decades. PCR allows a particular
DNA region, decided by the researcher, to be targeted and copied. (“Polymerase Chain
Reaction”, 2017) Generally, a researcher would want multiple copies of a specific region to
analyze it for certain characteristics or functions or pathogen identification. (Järvinen, 2009) (See
Figure 1)
For PCR to function, a DNA polymerase enzyme is required to make new strands of
DNA. Taq polymerase is the most common DNA polymerase used for PCR. This particular
polymerase is derived from a heat-tolerant bacterium, making it ideal in PCR. PCR uses high
temperatures at many points in the process to denature the template DNA. (“Polymerase Chain
Reaction”, 2017) For the polymerase to work, a primer is needed. Two primers are used in a
PCR experiment; these primers are short pieces of single-stranded DNA. Each primer is tasked
with surrounding the target region of DNA and binding to opposite strands of the template DNA,
leaving the target region unbound. (“Polymerase Chain Reaction”, 2014) When the strands are
cooled, the primers are allowed to bind to the template. Once they are bound, the temperature is
increased allowing synthesis of new DNA. This process occurs 25-35 times in a single PCR
experiment. Each experiment takes between two and five hours. The time will depend on the
length of the DNA sequence that is targeted and being copied. (“Polymerase Chain Reaction”,
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2014) After the reaction is complete, gel electrophoresis is often used to visualize the reaction.
(See Figure 2) This process takes between 1 and (Järvinen, 2009) 1.5 hours. (“Agarose Gel
Electrophoresis”, n.d.) PCR can also be analyzed on a microarray. (Järvinen, 2009) Often, when
analyzing a PCR reaction, a researcher may find unexpected amplifications. A limitation of PCR
is its need for sample purity. If a contaminant is involved in the reaction, the contaminant may be
copied as well, skewing the results. (Brookman-Amissah, 2014) Extra steps to prevent
contamination between samples must be taken.

Confirming Active Pathogens Through Unamplified RNA Expression™
Confirming Active Pathogens Through Unamplified RNA Expression is a method
developed by GeneCapture, Inc. to be used as a rapid diagnostic tool. CAPTURE™ uses a stemloop captor to identify pathogens. The stem is a specific sequence that does not change. The loop
is a unique sequence from the pathogen(s) that the specific panel is trying to identify.
The CapLab is the machine, designed by GeneCapture, to carry out the CAPTURE™
process. A lysate from a sample (in this case from urine) was placed in a cartridge along with
buffers and targets. The sample is run across an array of appropriate stem-loop captors. If the
sequence of the sample finds a match in one of the loops, it will bind. Once the sample binds, the
loop is forced to open and a oligonucleotide binds to the hanging stem. This oligo acts as the
detector, producing the signal needed to analyze. (Boeteng, 2013) (See Figure 3) After this
process, the array is cooled back down to allow the loops with no binding to close. The
microarray can then be analyzed for the specific pathogen. (Boeteng, 2013) (See Figure 4)
CAPTURE™ looks at expressed RNA rather than rDNA. It has the ability to target hundreds of
pathogens in a single assay. (Pusey, Chittur, 2007) Captors do have the potential to cross-react
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with other species but statistical cluster analyses are completed to counter this possibility. For
more information regarding the specific binding processes and hybridization, refer to Novel
stem-loop probe DNA arrays: Detection of a specific acetotrophic 16s ribosomal RNA
signatures, 2012, Jonas Boateng, Robert Zahorchak, Joel Peek, & Krishnan Chittur.

PCR & CAPTURE™ Comparison

Disease Coverage
Specificity

Cost
Sample Turn-AroundTime
Primer Binding

PCR
Looks at one pathogen at a
time
Sample purity is key,
contaminates are often
amplified or duplicated
>$100/test
few hours to days
rDNA

CAPTURE™
Targets hundreds of pathogens
in a single assay
Crude lysates from any matrix
(urine, blood, saliva)
~$20/test
Currently 1 hour, goal <30
minutes
Expressed RNA

In the this table, the CAPTURE™ diagnostic is compared to multiplex PCR.

Urinary Tract Infections
Many factors, lifestyles, and diagnoses such as an active sexual life, menopause, diabetes,
difficulty emptying the bladder, or obstruction may lead to urinary tract infections. All of these
factors influence the high occurrence rate of UTIs, especially among women. Research has
shown that 40 to 60 percent of women will have at least one urinary tract infection in their lives.
(Stapleton, 2017) Male and female UTIs add up to approximately 150 million cases worldwide
per year related with an estimated $6 billion dollar healthcare expenditure. (Baldato, 2016) Due
to the rate of occurrence, ease of access, and the need for rapid identification, this study chose to
collect and analyze suspected UTI samples. The current method for identifying pathogens in
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human urine samples is a lengthy process, usually taking two to three days to complete. First, a
clean catch midstream void is collected and then a dipstick urinalysis is performed, ending with a
quantitative urine culture completed by a lab. (Baldato, 2016) Due to this delay in a specific
diagnosis of the infecting pathogen, a broad-spectrum antibiotic is often given. (Zeeman, 2007)
If the culture results differ from the original speculation and the antibiotic given does not hinder
the pathogen identified as the infectant, the patient has received an unnecessary treatment that
could later lead to antibiotic resistance. (Ventola, 2017) Additionally, if the pathogen is not
identified rapidly, the pathogen has the potential to mutate and move, causing acute
pyelonephritis (kidney infection). (“Urinary Tract Infections”, 2017)

Antibiotic Resistance
Antibiotic resistance is the ability of bacteria to resist the effects of antimicrobial agents;
this is either innate or acquired. Acquired resistance is of more concern due to the possibility of
rendering currently effective drugs, ineffective. (Burchum, 2016) Over time, bacteria may
become less sensitive to an antibiotic or may lose all sensitivity. (Burchum, 2016) Antibiotic
resistance is increasing due to overuse and misuse of antibiotics (“Get Smart”, 2014), extended
hospitalization (Burchum, 2016), and antibiotic use among food sources i.e. giving animals
antibiotics (“Get Smart”, 2014). Research studies have shown that 30 to 50 percent of antibiotics
given were incorrect for the infection or the duration of the treatment. (Ventola , 2017)
Antibiotics are only effective against bacteria, not viruses or fungi. These agents are not effective
against common colds, gastrointestinal viruses, the flu, most sinus infections, or ear infections
(“Get Smart”, 2014); however, they are often prescribed for these diagnoses due to delayed
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diagnostic testing to identify the specific infecting pathogen, patient knowledge deficit, and
improper provider prescriptions. (See Figure 4)

Methods
Captor Design
Captor design is crucial to the functionality of the CAPTURE™ method. The purpose of
the captor design process is to identify a sequence unique to each pathogen with little to no
crossover with other species. Some pathogens fall in the same phylum or genus but still need to
be differentiated to come to a proper diagnosis. There is still the potential of crossover between
species; therefore, statistical cluster analyses were completed to account for the potential
interactions. GeneCapture owns a proprietary software program that utilizes uploaded genomic
information of the most highly expressed genes to seek out sequences that are common to an
individual pathogen but also retain unique areas that set it apart from other any others. The
sequences are then attached to the ‘universal stem’ and placed on the array. Though the captor
design process looks for a unique sequence for each pathogen, it still must take into account the
constantly changing nucleic acids in each organism. For this reason, multiple captors are
designed for each pathogen and placed on the array; up to 5 captors will be used for one
pathogen. Positive and negative controls are included on each array.

Sample Acquisition
Samples were gathered from patients with suspected UTIs that presented to the
University of Alabama in Huntsville’s Faculty & Staff Clinic, a division of the College of
Nursing. The staff of the clinic asked the patients if they would give two samples, one for regular
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lab testing and one to be given to GeneCapture for testing. Patients were made aware that none
of their personal information would be given to GeneCapture or be used for the study. The
samples were considered discarded and de-identified. Samples were kept in a refrigerator at the
clinic till time of acquisition. The samples were then transported, by a GeneCapture staff
member, to the lab in a marked biohazard container.

Sample Prep
To prepare each sample received from the clinic, a specific series of manual steps were
followed. In this process a lysis buffer was used to break open the cells of the pathogen and
fragment the RNA. (The specific process and lysis buffer have been excluded from this text for
proprietary reasons). After the steps were completed, a sample of the lysate was plated to
confirm sterility. In addition, through dilution plating, a portion of each original urine sample
was used to confirm and compare growth and identity of the pathogen with the results received
from the clinic’s contracted laboratory.

Sample Testing
The lysate along with the buffers (the specific buffers have been excluded from this text
for proprietary reasons) are paced in a cartridge designed specifically for the CapLab. The
machine uses a simple pump, like that used in a common aquarium, to move a succession of
fluids (the lysate and buffers) across the array. As the fluid move across the array, the target
(lysate) binds to the corresponding captors. A rinse is then completed to wash away any excess
target. The fluorescent detector will then bind to the open captors and another rinse will be
completed. A final rinse is completed to stabilize duplex formation before scanning.
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Assay Analysis
The future of the CapLab will allow the assay analysis and, therefore the identification of
the pathogen, to be completed within the CapLab itself. (See Figure 6). During this study a
GenePix 4200b Scanner (Molecular Devices, Inc, Sunnyvale, CA) was used to scan the resulting
microarrays containing the now closed captors and bound florescence. (See Figure 4). With the
map of the placement of each captor, the pathogen was identified from the signal on the array.

Comparison
Once the assay was analyzed and the infecting pathogen determined by the CAPTURE™
method, the results were compared to the results given by the University’s contracted lab. The
results from the lab took 2-3 days to receive.

Optimization
After each sample was tested and analyzed, the process was scrutinized for areas that
needed improvement due to overlap, lack of specificity, and chemical change. During the time
that this particular study was completed, the lysis protocol was updated several times and captors
were redesigned.

Results
Sample

UAH001

Culture

CapLab

+/-

ID

+/-

(+)

Group B Strep

(-)

ID
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UAH002

(+)

E. coli

(-)

UAH003

(-)

Mixed flora

(-)

UAH004

(-)

No growth

(-)

UAH005

(+)

E. coli

(+)

UAH006

(-)

No growth

(-)

UAH007

(-)

No growth

(-)

UAH008

(-)

No growth

(-)

UAH009

(-)

No growth

(-)

UAH010

(-)

Mixed flora

(-)

UAH011

(+)

Group B Strep

(-)

UAH012

(-)

Mixed flora

(-)

UAH013

(+)

E. coli

(+)

E. coli

UAH014

(+)

K. pneumoniae

(+)

K. pneumoniae

UAH015

(-)

No growth

(-)

UAH016

(-)

Mixed flora

(-)

UAH017

(-)

No growth

(-)

UAH018

(-)

No growth

(-)

UAH019

(+)

E. coli

(+)

E. coli

E. coli

Shown above, the results from the contracted lab are compared to the results of the
CAPTURE™ assay. When a negative result was received from the CapLab and not the
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laboratory, the captors as well as the lysis protocol were analyzed for areas that needed
optimization. Some captors had to be redesigned to have a higher specificity and less overlap
with other species. The lysis protocol had to be adjusted to account for samples that yielded very
small amounts of lysate.
The CAPTURE™ results for sample UAH002 did not yield E.coli as the culture results
did. It was determined that the RNA extraction process for this sample resulted in too little
detectable RNA. E. coli was detected in future samples. Culture results for the samples UAH001
and UAH011 found Streptococcus agalactiae or Group B Strep. Further research showed that this
particular bacterium can be a cause of UTIs, a result of a kidney stone and can be very harmful
during pregnancy. No captors for this bacterium were on the panel used in this study; after
discussion, captors for this bacterium were designed and added to a new panel for future studies.
A lab culture of “mixed flora” indicates that only low levels of multiple bacteria were
grown but were not an indicator of infection. The mixed flora result was most likely yielded due
to a non-sterile urine sample. The urinary tract and urine are sterile unless contaminated by
pathogens. Normal flora are bacteria that live on or in a human body at all times. These bacteria
are not pathogenic and aid the body in fighting off harmful bacteria. Every person carries normal
flora in areas such as the gastrointestinal tract, nose, mouth, and skin, specifically, around the
genitals. Using a clean catch method to obtain a urine sample would eliminate this flora from
contaminating a sample; however, patients often complete the clean catch method incorrectly,
resulting in a contaminated sample. (See figure 7 for steps to gather a proper clean catch sample)
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Conclusion
This study that specifically looked at UTI samples to validate and optimize the
CAPTURE™ method is an ongoing study and is now being conducted alongside other more indepth studies at the GeneCapture lab. Through this research study, it was determined that the
CAPTURE™ method does have the ability to identify specific pathogens from human samples.
It was determined that the CAPTURE™ method can be completed in one hour with the direction
of being completed in less time as more steps in the process become a part of the automation of
the CapLab. Further optimization of the UTI captor panel is currently underway.
The CAPTURE™ method and this study have many implications for medical and nursing
practice. This form of rapid diagnostics allows for determination of the infecting pathogen in a
clinic and at the bedside for timely and accurate treatment, thereby reducing the exponential
growth in the number antibiotic resistant pathogens. This technology has the potential and
accessibility to be used in areas with little to no access to laboratories or medical facilities such
as: military camps, disaster areas, and wilderness/remote installments. There are possibilities for
use in pandemic emergence and tracking. CAPTURE™ can also be utilized in agriculture to
identify plant pathogens to reduce crop destruction and increasing food insecurity. There is also
potential for cancer detection and treatment monitoring. This research is ongoing and it will be
exciting to determine how, in the future, this technology will improve health outcomes.
Publication of the expanded validation study is expected in the near future.
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Figures
Figure 1

Example of PCR and copying of targeted areas of DNA. (“Polymerase Chain Reaction”, 2017)
Figure 2

Example of gel electrophoresis. (“Polymerase Chain Reaction”, 2017)
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Pathogenic nucleic acids pass over the captors on the microarray and bind to their complement
in the loop region; this binding forces the stem to open (the captors only remain open if the
correct target has bound). The captors that remain open then bind to a universal detector. The
microarray is washed stringently to remove any mismatched or unbound nucleotides. (Koelle,
2014)
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Figure 4

A"Typical"Microarray"Image"
Landing Lights !>#

Negative Control !>#

Circles are
around two of the
positive E. coli
captors

Positive Control !>#

<!#Landing Light

7"

Microarray. Identifies which captors bound to the sample. The fluorescent detector shows the
signal from each bound captor. The ‘landing lights’ allow the person analyzing to orient the
direction of the array and to correctly identify which captors bound. (Koelle, 2014)
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Figure 5

Explanation for the development and exponential growth of antibiotic resistance. (“Antibiotic
Resistance”, n.d.)
Figure 6

Vision for future CapLab design.
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Figure 7

(Maher, 2017)
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Appendix A: IRB
A-1

THE UNIVERSITY OF ALABAMA IN HUNTSVILLE

FORM 1: INSTITUTIONAL REVIEW BOARD APPLICATION
Instructions: In MS Word, highlight the shaded underlined box and replace with
your text. Double-click checkboxes to check/uncheck. Provide
signatures by typing in your name where appropriate. See submission
instructions at the end of this form.
Principal Investigator/Study Director Name:
Status: Faculty
Department:

Dr. Louise O'Keefe

Staff

Student

College/Research Center: Nursing

Telephone: 256-824-2100

Email: louise.okeefe@uah.edu

Supervising Faculty Information (if student)
Name:
Campus Address:
Telephone:

Email :

Funding: External

Internal

Unfunded

Funding source (if applicable):
Title of Study: (Summarize the purpose/objectives of this study in nontechnical, lay language).
Preliminary Validation of CAPTURE rapid diagnostic protocol on UTI samples.
Purpose of Study: To assist a local R&D company by supplying human urine samples to allow preliminary validation
of their molecular diagnostic technique. The company, GeneCapture, is an associate company at HudsonAlpha
Institute for Biotechnology and is developing a technique that was patented by UAH and licensed to
GeneCapture for commercialization as a rapid diagnostic. This project includes participation of a UAH Nursing
student.

State the Hypotheses, Research Question, or Practice Question: A rapid diagnosis of UTI can be accomplished in
about 1 hour using a novel molecular diagnostic technique that determines a genetic match using DNA probes.

Description of Subjects: (Please identify the anticipated sample size and where these participants
will be recruited from. Summarize participant characteristics such as age, sex, race/ethnicity, and
health status. If a special population (e.g. children or prisoner) will be included, provide a brief
justification, and include form 6 if subjects are 18 or younger or form 7 if a prisoner.)
Participants will be adult patients of the UAH Faculty and Staff clinic who agree to allow their otherwise discarded
urine sample to be used for research. It is expected that about 30 participants will be included during the
summer months of 2016.

Updated:2/2016
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How Subjects Will Be Selected and Recruited: Adult patients who come to the UAH Faculty and Staff clinic with
UTI symptoms will be notified by staff, that a research test is underway and that they may elect to participate
by allowing their otherwise discarded urine to be used for research. See flyer provided by GeneCapture.
x

Summarize selection process such as random method, snowballing, convenience sampling etc. and your
ability to access the population.

x

Please identify the institution, clinic, or site from which participants are to be recruited. Describe your
procedures for identifying and recruiting subjects.

x

How will subjects be identified and by whom?

x

How will initial contact be made with prospective subjects and by whom (include a script if applicable)?

x

Please describe and provide a copy of all recruitment materials such as flyers, email invitations, student

x

ALL OF THESE MATERIALS MUST BE REVIEWED AND APPROVED BY THE IRB PRIOR TO USE.

subject pool posting, social media postings, etc.

Background and qualifications of the principal investigator and additional personnel directly involved in the
research: __Dr. O’Keefe has all the required training to conduct this study. Dr. O’Keefe’s research experience
focuses on employee health and includes studies on obesity, prediabetes and stress in municipal employees,
the effect of air pollution on cardiovascular health, colorectal cancer screening in employees, and cancer
survivorship in the workplace. Dr. O’Keefe is Director of the Faculty and Staff Clinic on the campus of UAH.

(Please briefly provide background information on the principal investigator (research background, human
subject testing certification, CITI training, etc.) as well as all other researchers involved in the study in any
capacity. This information may be attached as separate sheet as needed. Also include information pertaining
to the connection between the principal investigator and recruitment sites.)

Description of Procedure: (Summarize the process you will ask participants to follow. What will The subjects be
asked to do? Provide a copy of the research script if applicable. Briefly describe the setting in which the
research will be conducted.)

At any time during the visit to the clinic, the staff member will provide the patient with the flyer and ask if they
give permission to allow the otherwise discarded urine sample to be used for research by GeneCapture. The
patient will not be required to perform any extra steps.

Instrumentation (if applicable):

Updated:2/2016
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(Describe all materials such as questionnaires, surveys, cognitive tests, any and all designed materials or
measures, equipment, etc. to be used in the study, and provide a brief explanation for their use. Attach a copy
of these materials with your application.)

The patient will only be asked to sign the consent form if they so desire.

Duration of Study
a. Total amount of time with each subject: 10 minutes
b. Time to complete study:

About six months

Benefit(s) of the Study:
(Summarize any potential benefits to include physical, psychological, social, economic, and/or legal. These
benefits are to be included in consent form as well. Describe potential benefits/significance of the study to
science or society.) Benefits do not include incentives and compensation for participation in the study, see
below.
The current technique for identification of pathogens in human samples is lengthy. During the 2-3 day
turnaround time, the patient can become sicker, pathogens can mutate and unnecessary medications can be
prescribed. A rapid diagnostic will provide the patient and healthcare professional with a quicker diagnosis.
Incentives and compensation: Patients will not be compensated in this study
(Summarize the incentives for participation in the research for example gaining an insight into research, etc.
Summarize the compensation that will be received for participating in the research (for example research
credit hours for students, monetary incentives for non-students, etc.).
Possible Risks to Subject(s) and Precautions Taken to Avoid Risks:

None

(Summarize any potential risks to include physical, psychological, social, economic, and/or legal. These risks
are to be included in consent form as well.)

How You Will Ensure Confidentiality/Anonymity:
(Summarize provisions to protect privacy interests and the method for securely collecting, storing, and
possible disposal of research data. How confidentiality will be assured?)
The sample provided to GeneCapture will be de-identified. It will be marked with a number only. Only the UAH
clinic will have access to the patient name and number. At no time will patient identity be provided.
Procedures for attaining Informed Consent or Assent:
Describe the procedures to be used to obtain consent, the circumstances under which consent will be sought
and obtained, the timing of obtainment:
x

Will there be a delay between obtaining consent and actual participation in the research?

Updated:2/2016

VALIDATION & OPTIMIZATION OF CAPTURE™

xii

x

Which research personnel will obtain consent (please provide personnel qualifications as requested

x

What steps will be taken to minimize the possibility of coercion and/or undue influence?

x

If the study involves minors (under the age of 18) describe the procedure to obtain assent and how it will

above)?

be documented. Also include how parental permission for the participation of minors will be obtained and
documented.
x

Describe any and all procedures for reobtaining informed consent/assent (for example, in studies
involving multiple sessions) and how it will be documented.)

During the visit to the clinic, the staff will approach the UTI patient with the flyer from GeneCapture. If the patient
agrees to participate, the consent form will be provided to them and collected by the staff.

Documentation of Informed Consent by Subject(s) Attached? Yes X

No

(Attach consent form. Any waiver of consent justification needs to follow U.S. Health and Human Service
justification see links below for details.)
Documentation of all study personnel qualification(s) as stated above attached?
Yes X
Are copies of all materials as stated above attached? Yes X

No
No

http://www.hhs.gov/ohrp/policy/consentckls.html,
http://www.hhs.gov/ohrp/policy/checklists/decisioncharts.html#c11, or
http://www.hhs.gov/ohrp/policy/checklists/decisioncharts.html#c10.)

INVESTIGATOR ASSURANCE STATEMENT & SIGNATURE

By my signature as Principal Investigator, I acknowledge my responsibilities for this Human Subjects
Study and affirm that:

x
x
x
x

I have reviewed and will comply with the Belmont Report:
http://www.hhs.gov/ohrp/humansubjects/guidance/belmont.html,
I have reviewed and will comply with informed consent regulations:
http://www.hhs.gov/ohrp/policy/consent/index.html
I will report (and will instruct other key personnel to report) adverse or unanticipated problems to
chair of the IRB, 256-824-6100 or irb@uah.edu :
http://www.hhs.gov/ohrp/policy/advevntguid.html
I have reviewed and acknowledge the Investigator Responsibilities:
http://answers.hhs.gov/ohrp/categories/1567.
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x

I will not modify the protocol unless (a) the IRB has approved changes prior to implementation or
(b) it is necessary to eliminate an apparent, immediate hazard to a participant(s);
I will verify that all personnel are licensed/credentialed for the procedures they will be
performing, if applicable;
I will apply for continuing review of the protocol at least annually unless directed by the IRB to
apply more frequently;
I understand I may be audited;
I will conduct the protocol as represented here and in compliance with IRB determinations and all
applicable local, state, and federal law and regulations; and will provide the IRB with all
information necessary to review the protocol; and will refrain from protocol activities until
receipt of formal IRB approval.

CONFLICT OF INTEREST ACKNOWLEDGMENT
Federal Guidelines require assurances that there are no conflicts of interest in research
projects that could affect the welfare of human subjects. If this study presents a potential
conflict of interest, additional information will need to be provided to the IRB. Examples of
potential conflicts of interest in research involving human subjects may include, but are not
limited to:
• A researcher or family member participates in research on a technology, process or
product owned by a business in which the faculty member holds a
financial interest.
• A researcher or family member participates in research on a technology, process or
product developed by that researcher.
• A researcher or family member has a financial or other business interest in an entity which
is supplying funding, materials, products, or equipment for the current research project.
• A research or family member serves on the Board of Directors of a business which is
supplying funding, materials, products, or equipment for the current research project.
• A researcher receives consulting income from an entity that is funding the current
research project.
Do any members of the study team, or any of their family members, have a financial or
other business interest in the source(s) of funding, materials, or equipment
related to this research study?
Yes

NoX

If you answered yes, contact the IRB Chair.

“Family Members” is defined to include spouse or any dependent. “Dependent” is
any person, regardless of his or her legal residence or domicile, who receives 50
percent or more of his or her support from the Investigator or his or her spouse or
who resided with the Investigator for more than 180 days during the reporting
period.

Signature: ____Louise C. O’Keefe, PhD, CRNP_____Date: May 25, 2016
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Supervising Faculty Signature (if student):____________Date: ______________
This signature acknowledges I am the Principal Investigator and/or Supervising Faculty.

Submission Instructions:

Save file as a pdf file with the extension form 1 (investigator’s last name
first initial) (year month date). Example: form1smithj20130401. This will
be J. Smith submitting a proposal on April 1, 2013 as a first submission.
If multiple submissions are provided in a single day, append a letter a-z
at end of file name. Submit electronically to irb@uah.edu.
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FORM 2: Application for Expedited Review by
UAH Human Subject Committee
Name: _Louise O'Keefe_________________________________________ Date: _May 1, 2016___________
Address:____327 Wilson Hall__________________________________________________
City, State, Zip __Huntsville, AL _____35899__________________________________________
Telephone: ( 256 ) 824-2100_____UAH Email: __louise.okeefe@uah.edu_____________
PI and Faculty Supervisor (if applicable): __Louise C. O’Keefe, PhD, CRNP_____May 25, 2016
Signature

Date

____________________________________________________
Signature

Date

Research conducted may receive expedited review by the UAH HSC if the research involves no more
than minimal risk and fully meets at least one of the following (please check all that apply):
___Clinical studies of drugs and medical devices only when condition (a) or (b) is met. (a) Research on drugs for which an investigational new drug
application (21 CFR Part 312) is not required. (Note: Research on marketed drugs that significantly increases the risks or decreases the acceptability
of the risks associated with the use of the product is not eligible for expedited review. (b) Research on medical devices for which (i) an
investigational device exemption application (21 CFR Part 812) is not required; or (ii) the medical device is cleared/approved for marketing and the
medical device is being used in accordance with its cleared/approved labeling.
___Collection of blood samples by finger stick, heel stick, ear stick, or venipuncture as follows: (a) from healthy, nonpregnant adults who weigh at
least 110 pounds. For these subjects, the amounts drawn may not exceed 550 ml in an 8 week period and collection may not occur more frequently
than 2 times per week; or (b) from other adults and children, considering the age, weight, and health of the subjects, the collection procedure, the
amount of blood to be collected, and the frequency with which it will be collected. For these subjects, the amount drawn may not exceed the lesser of
50 ml or 3 ml per kg in an 8 week period and collection may not occur more frequently than 2 times per week.
___xProspective collection of biological specimens for research purposes by noninvasive means. Examples: (a) hair and nail clippings in a
nondisfiguring manner; (b) deciduous teeth at time of exfoliation or if routine patient care indicates a need for extraction; (c) permanent teeth if
routine patient care indicates a need for extraction; (d) excreta and external secretions (including sweat); (e) uncannulated saliva collected either in an
unstimulated fashion or stimulated by chewing gumbase or wax or by applying a dilute citric solution to the tongue; (f) placenta removed at delivery;
(g) amniotic fluid obtained at the time of rupture of the membrane prior to or during labor; (h) supra- and subgingival dental plaque and calculus,
provided the collection procedure is not more invasive than routine prophylactic scaling of the teeth and the process is accomplished in accordance
with accepted prophylactic techniques; (i) mucosal and skin cells collected by buccal scraping or swab, skin swab, or mouth washings; (j) sputum
collected after saline mist nebulization.
___Collection of data through noninvasive procedures (not involving general anesthesia or sedation) routinely employed in clinical practice,
excluding procedures involving x-rays or microwaves. Where medical devices are employed, they must be cleared/approved for marketing. (Studies
intended to evaluate the safety and effectiveness of the medical device are not generally eligible for expedited review, including studies of cleared
medical devices for new indications).
___Research involving materials (data, documents, records, or specimens) that have been collected, or will be collected
solely for nonresearch purposes (such as medical treatment or diagnosis).
_____ Collection of data from voice, video, digital, or image recordings made for research purposes.
_____ Research on individual or group characteristics or behavior (including, but not limited to, research on perception, cognition, motivation,
identity, language, communication, cultural beliefs or practices, and social behavior) or research employing survey, interview, oral history, focus
group, program evaluation, human factors evaluation, or quality assurance methodologies.

I hereby certify that my research fully meets the categories indicated above. In the event that my
research becomes ineligible for such expedited review, for any reason, I will re-apply for appropriate
UHSC review.
____Louise C. O’Keefe______________________________________________May 25, 2016___________________
Signature
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Checklist: New, Expedited Review Submission
(Rev. 04/2013)
Submissions must be saved in pdf format and sent to irb@uah.edu

Completed and electronically signed IRB Application for Expedited Review by UAH HSC
One copy of the signed Institutional review board application (Form 1).
One copy of your Consent Form. If you wish to waive the required consent form, please state in
your application why a waiver of consent is justified. Please see Consent Forms at
www.uah.edu/irb. In order to waive consent, you need to meet the HHS guidelines
For research involving children and/or minors less than 19 years of age, one copy of a
memorandum from the Principal Investigator which must address the Children’s Risk Level
assessment (see Form 6 at www.uah.edu/irb)

Include instrument/surveys/questionnaires as applicable for review.

¾

Make sure you have checked the IRB web page (http://www.uah.edu/irb)
for the most current consent form format.

Submit all materials in electronic form to irb@email.uah.edu.
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July!7, 2016
Dr. Louise O’Keefe
Assistant Professor
College of Nursing
University of Alabama in Huntsville
Dear Dr. O’Keefe,
The UAH Institutional Review Board of Human Subjects Committee has reviewed your
proposal, “Preliminary Validation of CAPTURE rapid diagnostic protocol on UTI samples”, and
found it meets the necessary criteria for congtingent approval. Your proposal seems to be in
compliance with this institutions Federal Wide Assurance (FWA) 00019998 and the DHHS
Regulations for the Protection of Human Subjects (45 CFR 46).
Please note that this approval is contingent upon receiving finalized versions of the both a
Material Transfer Agreement and a Memoraduum of Understanding with GeneCapture Inc.,
within 30 days from the date on this letter. Once those are received, we will send a final letter of
approval. At this stage we know that the current drafts of both these documents appear to be in
final form and are merely awaiting signatures.
Even though this approval is contingent, no changes are to be made to the approved
protocol without prior review and approval from the UAH IRB. All changes (e.g. a change in
procedure, number of subjects, personnel, study locations, new recruitment materials, study
instruments, etc) must be prospectively reviewed and approved by the IRB before they are
implemented. You should report any unanticipated problems involving risks to the participants
or others to the IRB Chair.
If you have any questions regarding the IRB’s decision, please contact me.

Sincerely,

William Wilkerson
IRB Chair
Dean, Honors College
OFFICE OF THE VICE PRESIDENT FOR RESEARCH
Von Braun Research Hall M-17
Huntsville, AL 35899

T 256.824.6100

F 256.824.6783
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September 15th 2016
Louise C. O'Keefe, PhD, CRNP
Assistant Professor, College of Nursing
Chair, Faculty Organization, College of Nursing
University of Alabama in Huntsville
Dear Dr. O’Keefe,
The UAH Institutional Review Board of Human Subjects Committee has reviewed your
proposal, Preliminary Validation of CAPTURE rapid diagnostic protocol on UTI samples., and
found it meets the necessary criteria for continued approval. Your proposal seems to be in
compliance with this institutions Federal Wide Assurance (FWA) 00019998 and the DHHS
Regulations for the Protection of Human Subjects (45 CFR 46).
Please note that this approval is good for one year from the date on this letter. If data
collection continues past this period, you are responsible for processing a renewal application a
minimum of 60 days prior to the expiration date.
No changes are to be made to the approved protocol without prior review and approval
from the UAH IRB. All changes (e.g. a change in procedure, number of subjects, personnel,
study locations, new recruitment materials, study instruments, etc) must be prospectively
reviewed and approved by the IRB before they are implemented. You should report any
unanticipated problems involving risks to the participants or others to the IRB Chair.
If you have any questions regarding the IRB’s decision, please contact me.

Sincerely,

William Wilkerson
IRB Chair
Dean, Honors College

OFFICE OF THE VICE PRESIDENT FOR RESEARCH
Von Braun Research Hall M-17
Huntsville, AL 35899

T 256.824.6100

F 256.824.6783
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Appendix B: Consent Documents
B-1

GeneCapture is a company at HudsonAlpha
Institute for Biotechnology, that is
developing a rapid infection detection
product. We need to validate that our
results work on actual human samples.
Today, when you provide a urine sample to
the staff, they will use a portion of it and
then discard the rest. With your permission we would
like to use the discarded portion for our research.
We will have NO ACCESS to your identification.
Thank you for helping us advance this important
research into finding faster ways to identify infections –
and we hope you feel better soon!

GeneCapture is a company at HudsonAlpha
Institute for Biotechnology, that is
developing a rapid infection detection
product. We need to validate that our
results work on actual human samples.
Today, when you provide a urine sample to
the staff, they will use a portion of it and
then discard the rest. With your permission we would
like to use the discarded portion for our research.
We will have NO ACCESS to your identification.
Thank you for helping us advance this important
research into finding faster ways to identify infections –
and we hope you feel better soon!
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Written Consent to Participate in Research
I understand that researchers from GeneCapture, Inc., a company at
HudsonAlpha Institute for Biotechnology are trying to develop a rapid way to
identify germs in urine. I am willing to help with the study. I understand
that I can help by allowing the extra urine collected from me today to be
used by the researchers for testing. I understand that my urine sample is
being provided without any information that identifies me. There is no
foreseeable risk attached to participating in this study.

_____________________________________name

______________________________________ signature

______________________ date
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Appendix C: Dissemination of Scholarly Work, Publications, & Awards
C-1
Event/Location: Hudson Alpha BioTrain Internship Poster Presentation, Huntsville, AL
Date: July 2016
Description: HudsonAlpha offers the BioTrain Internship program each summer to allow
students to experience various aspects of the biotechnology community. At the end of the
internship, the student presents a poster to HudsonAlpha/the public of their work and research
from the program.

Preliminary Validation of CAPTURE with UTI Samples
Elizabeth Gates, Paula M. Koelle, Dr. Louise O’Keefe
Introduction
The current method for identifying pathogens in human urine samples is a lengthy process, usually taking 2-3 days to
complete. During this delay period, the patient may become sicker, the pathogens may mutate, and unnecessary or
incorrect treatments and antibiotics may be administered. There is a need for a more rapid diagnostic method to provide
the patient and healthcare provider an immediate diagnosis. The rapid diagnostic method being tested has been coined the
CAPTURE method, created by GeneCapture. The CAPTURE (Conﬁrming Active Pathogens Through Unampliﬁed RNA
Expression) method uses a molecular diagnostic technique to determine a genetic match for the pathogen using DNA
captors that will identify the pathogen in less than one hour for minimal expense.

CAPTURE

Collaboration
UAH Faculty/Staff Clinic:
Interprofessional collaboration with UAH Faculty/
Staff Clinic to receive urine specimens from patients
with suspected UTIs
Institutional Review Board:
• Approve, monitor, and review research involving
humans via risk-beneﬁt analysis and ethics
• Patients each receive a consent form &
explanation of experiment
• Approval received from the UAH IRB of Human
Subjects Committee

Methods
Captor Design: designate a sequence
unique to each urinary tract pathogen –
no crossover between captors
Sample Collection:
Retrieval of de-identiﬁed, discarded urine
specimen from UAH Clinic: samples are
clean catch
Sample Preparation:
Lyse sample cells, dilute/plate portion of
original sample & lysate
Sample Testing:
Run sample through automated
CAPTURE in CapLab in under 40 min
Sample Reading:
View microarray on GenePix Scanner
Compare CAPTURE microarray results
to culture results

Pathogenic nucleic acids pass over the captors on the microarray and bind to their
complement in the loop region; this binding forces the stem to open (the captors only
remain open if the correct target has bound). The captors that remain open then bind to a
universal detector. The microarray is washed stringently to remove any mismatched or
unbound nucleotides.

Results
Sample Number Culture

CapLab

UAH001

Negative

Negative

UAH002

+ (E. coli) Negative

UAH003

Negative

Concentration of Ec6S vs SNR
40

Negative

Sample results as of 7-18-16

Samples were run across a panel that covered
captors for many pathogens including 8 of the most
common for urinary tract infections such as: E. coli
& Klebsiella. The samples were found on the
CapLab to be negative for all pathogens in the
panel. The culture reports found that there were no
pathogens other than normal urogenital ﬂora. Note:
Culture for UAH001 found Streptococcus agalactiae in the
urine sample as a result of a kidney stone. Further
research showed that this bacteria can be a cause of UTIs
and very harmful during pregnancy – a captor for this
bacteria will be added to the panel in the future.

Vision for ﬁnal CapLab
Acknowledgements
• GeneCapture: Peggy Sammon, CEO; Dr. Krishnan
Chittur, CTO & UAH Prof. of Chem Engineering
• UAH Faculty and Staff Clinic: Dr. Louise O’Keefe,
PhD, CRNP & Amber McPhail, MSN, CRNP
• Microarrays, Inc.

35

30

picomolar of Ec6S

• Ability to target hundreds of
pathogens in a single assay (more
than PCR)
• Exploits the thermodynamics of
structured DNA
• Use of stem-loop captors on a
microarray
• Universal stem design with
pathogen-speciﬁc DNA loop

25
25

20

15
10
10

5
0
0
0

2.5

5

7.5

10

12.5

15

17.5

20

22.5

-5

SNR above Background

Recent detectable concentrations of
E. coli via Ec6 captor

Implications for Practice
•Rapid diagnosis & determination of
pathogen in clinic for timely &
accurate treatment
•Use in areas with no access to labs
or other medical facilities i.e. military
missions, disaster areas
•Potential use for pandemic
emergence & tracking
•Potential uses for agriculture &
identiﬁcation of plant pathogens
•Potential for cancer detection and
treatment monitoring

25
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C-2
Event/Location: National Conferences on Undergraduate Research, Memphis, TN
Date: April 2017
Description: Accepted as a poster presenter for National Conferences on Undergraduate
Research. This is a nationally recognized conference that allows undergraduate students from all
institutions to come together and present their research, as well as view their peers’ research.

National Conferences on
Undergraduate Research
April 6-8, 2017

Preliminary Validation of CAPTURE
with UTI Samples
Elizabeth Gates, BSN Student & Dr. Louise O’Keefe, PhD,
CRNP, College of Nursing, Paula Koelle, GeneCapture
Purpose

Key Findings

The current method for identifying pathogens in human
urine samples is a lengthy process, usually taking 2-3
days to complete. During this delay period, the patient
may become sicker, the pathogens may mutate, and
unnecessary or incorrect treatments and antibiotics
may be administered. There is a need for a more rapid
diagnostic method to provide the patient and healthcare
provider an immediate diagnosis. The rapid diagnostic
method being tested has been coined the CAPTURE
method, created by GeneCapture. The CAPTURE
(Confirming Active Pathogens Through Unamplified
RNA Expression) method uses a molecular diagnostic
technique to determine a genetic match for the
pathogen using DNA captors that will identify the
pathogen in less than one hour for minimal expense.

Sample

Culture

CapLab

UAH001
UAH002
UAH003
UAH004
UAH005
UAH006
UAH007
UAH008
UAH009
UAH010
UAH011
UAH012
UAH013
UAH014
UAH015
UAH016
UAH017
UAH018
UAH019

Group B Strep
E. coli
Mixed ﬂora
No Growth
E. coli
No Growth
No Growth
No Growth
No Growth
Mixed ﬂora
Group B Strep
Mixed ﬂora
E. coli
K. pneumoniae
No Growth
Mixed ﬂora
No Growth
No Growth
E. coli

(-)
(-)
(-)
(-)
E. coli
(-)
(-)
(-)
(-)
(-)
(-)
(-)
E. coli
K. pneumoniae
(-)
(-)
(-)
(-)
E. coli

Note: Samples were run across a panel that covered
captors for many pathogens including 8 of the most
common for urinary tract infections such as: E. coli &
Klebsiella. Culture for UAH001 and UAH011 found

Streptococcus agalactiae.. Further research showed
that this bacteria can be a cause of UTIs, a result of
a kidney stone, & very harmful during pregnancy – a
captor for this bacteria will be added to the panel in
the future.

Implications for Practice
Pathogenic nucleic acids pass over the captors on the microarray
and bind to their complement in the loop region; this binding forces
the stem to open (the captors only remain open if the correct target
has bound). The captors that remain open then bind to a universal
detector. The microarray is washed stringently to remove any
mismatched or unbound nucleotides.

Methods
Captor Design

Sample CollecBon

Culture Results Comparison

Results Analysis

Sample PreparaBon

Microarray Analysis

CAPTURE

1) Rapid diagnosis & determination of
pathogen in clinic for timely & accurate
treatment
2) Use in areas with no access to labs or
other medical facilities i.e. military
missions, disaster areas
3) Potential use for pandemic emergence &
tracking
4) Potential uses for agriculture &
identiﬁcation of plant pathogens
5) Potential for cancer detection and
treatment monitoring

Captor Redesign/Method OpBmizaBon

Vision for ﬁnal CapLab

Acknowledgements
GeneCapture: Peggy Sammon, CEO, Dr. Krishnan Chittur,
CTO; UAH Faculty & Staff Clinic: Amber McPhail, MSN,
CRNP; Microarrays, Inc.; HudsonAlpha Institute for
Biotechnology BioTrain Internships
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C-3
Event/Location: The University of Alabama in Huntsville, Huntsville, AL
Date: April 2017
Description: Accepted as a poster presenter for Research Horizons Day & Research Week. This
event at the University of Alabama in Huntsville allows undergraduate students from all majors
to come together and present their research, as well as view their peers’ research.
Awards: Recipient of University of Alabama in Huntsville Research Horizons Day,
Undergraduate Nursing Award

Research Horizons Day
& Research Week
April 11-14, 2017

Preliminary Validation of CAPTURE
with UTI Samples
Elizabeth Gates, BSN Student & Dr. Louise O’Keefe, PhD,
CRNP, College of Nursing, Paula Koelle, GeneCapture
Purpose

Key Findings

The current method for identifying pathogens in human
urine samples is a lengthy process, usually taking 2-3
days to complete. During this delay period, the patient
may become sicker, the pathogens may mutate, and
unnecessary or incorrect treatments and antibiotics
may be administered. There is a need for a more rapid
diagnostic method to provide the patient and healthcare
provider an immediate diagnosis. The rapid diagnostic
method being tested has been coined the CAPTURE
method, created by GeneCapture. The CAPTURE
(Confirming Active Pathogens Through Unamplified
RNA Expression) method uses a molecular diagnostic
technique to determine a genetic match for the
pathogen using DNA captors that will identify the
pathogen in less than one hour for minimal expense.

Sample

Culture

CapLab

UAH001
UAH002
UAH003
UAH004
UAH005
UAH006
UAH007
UAH008
UAH009
UAH010
UAH011
UAH012
UAH013
UAH014
UAH015
UAH016
UAH017
UAH018
UAH019

Group&B&Strep
E.&coli
Mixed&ﬂora
No&Growth
E.&coli
No&Growth
No&Growth
No&Growth
No&Growth
Mixed&ﬂora
Group&B&Strep
Mixed&ﬂora
E.&coli
K.&pneumoniae
No&Growth&&
Mixed&ﬂora
No&Growth
No&Growth&&
E.&coli

(,)
(,)
(,)
(,)
E.&coli
(,)
(,)
(,)
(,)
(,)
(,)
(,)
E.&coli
K.&pneumoniae
(,)
(,)
(,)
(,)
E.&coli

Note: Samples were run across a panel that covered
captors for many pathogens including 8 of the most
common for urinary tract infections such as: E. coli &
Klebsiella. Culture for UAH001 and UAH011 found

Streptococcus agalactiae.. Further research showed
that this bacteria can be a cause of UTIs, a result of
a kidney stone, & very harmful during pregnancy – a
captor for this bacteria will be added to the panel in
the future.

Implications for Practice
Pathogenic nucleic acids pass over the captors on the microarray
and bind to their complement in the loop region; this binding forces
the stem to open (the captors only remain open if the correct target
has bound). The captors that remain open then bind to a universal
detector. The microarray is washed stringently to remove any
mismatched or unbound nucleotides.

Methods
Captor&Design&&

Sample&CollecBon&&

Culture&Results&Comparison&&

Results&Analysis&

Sample&PreparaBon&&

Microarray&Analysis&

CAPTURE&

Captor&Redesign/Method&OpBmizaBon&

Acknowledgements
GeneCapture: Peggy Sammon, CEO, Dr. Krishnan Chittur,
CTO; UAH Faculty & Staff Clinic: Amber McPhail, MSN,
CRNP; Microarrays, Inc.; HudsonAlpha Institute for
Biotechnology BioTrain Internships

1) Rapid diagnosis & determination of
pathogen in clinic for timely & accurate
treatment
2) Use in areas with no access to labs or
other medical facilities i.e. military
missions, disaster areas
3) Potential use for pandemic emergence &
tracking
4) Potential uses for agriculture &
identiﬁcation of plant pathogens
5) Potential for cancer detection and
treatment monitoring

Vision for ﬁnal CapLab
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C-4
Publications:
Manuscript submitted to and under review by The University of Alabama in Huntsville Perpetua
Journal of Undergraduate Research.

